Moderna Inc (Symbol: MRNA) shares surged past the average analyst 12-month target price of $136.15, trading at $141.04 as of the latest market session. This rise prompts analysts to consider either downgrading the stock’s valuation or raising their target price, with a current range of estimates from $60.00 to as high as $310.00. The average target reflects contributions from 19 analysts, with a standard deviation of $59.718.
Currently, analyst ratings for Moderna include 8 strong buy, 1 buy, 10 hold, and 2 strong sell ratings, maintaining a consistent rating average of 2.38 on a scale where 1 is strong buy and 5 is strong sell. Investors are encouraged to reassess the company’s potential following the stock’s recent performance.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
